Clinical Trials

Sponsor: BioAlta, LLC

Sponsor Study ID: BA3011-002

Study Title: A Phase 2 Study of Mecbotamab Vedotin (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non Small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on or Are Intolerant to a PD 1/L 1, EGFR, or ALK Inhibitor

CTO #: 103390

NCT Number: NCT04681131

Phase: II

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Lung

Study Objectives: To assess antitumor activity of BA3011 alone and in combination with nivolumab. To assess the safety of BA3011 alone and in combination with nivolumab.



Study Documents    
(MUSC NetID required for document access)